Abbvie Inc’s recent filing unveils that its Former Director Richard A. Gonzalez acquired Company’s shares for reported $13.23 million on Aug 22 ’25. In the deal valued at $210.84 per share,62,755 shares were bought.
Then, Richard A. Gonzalez bought 90,000 shares, generating $18,993,948 in total proceeds.
Before that, SALEKI-GERHARDT AZITA sold 42,370 shares. Abbvie Inc shares valued at $8,407,055 were divested by the EVP, CHIEF OPERATIONS OFFICER at a price of $198.42 per share. As a result of the transaction, SALEKI-GERHARDT AZITA now holds 177,292 shares, worth roughly $38.34 million.
A number of analysts have revised their coverage, including Daiwa Securities’s analysts, who increased its forecast for the stock in early August from “a Neutral” to “an Outperform”. Citigroup also remained covering ABBV and has decreased its forecast on May 14, 2025 with a “Neutral” recommendation from previously “Buy” rating. Cantor Fitzgerald started covering the stock on April 22, 2025. It rated ABBV as “an Overweight”.
Price Performance Review of ABBV
On Tuesday, Abbvie Inc [NYSE:ABBV] saw its stock fall -0.62% to $216.26. Over the last five days, the stock has gained 2.78%. Abbvie Inc shares have risen nearly 11.46% since the year began. Nevertheless, the stocks have risen 21.70% over the past one year.
How much short interest is there in Abbvie Inc?
A steep rise in short interest was recorded in Abbvie Inc stocks on 2025-08-29, growing by 0.27 million shares to a total of 15.4 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 15.13 million shares. There was a rise of 1.76%, which implies that there is a positive sentiment for the stock.
